Skip to main content
  • King's Health Partners Rare Disease Grand Round: Hepatobiliary disease
1 of 3

King's Health Partners Rare Disease Grand Round: Hepatobiliary disease

Mon 3 Nov 2025 1:00 PM - 2:00 PM GMT Online, MS Teams

King's Health Partners Rare Disease Grand Round: Hepatobiliary disease

Mon 3 Nov 2025 1:00 PM - 2:00 PM GMT Online, MS Teams

Need help?

Manage tickets

Join us for our upcoming Rare Disease Grand Round hosted by the King's Health Partners Rare Disease Network

The King's Health Partners Rare Disease Network brings together research and clinical groups across the region, facilitating networking opportunities and creating a collaborative environment for cross organisational rare disease research​. By enhancing collaboration, scale, and impact of research, the network aims to attract future investment in translational rare diseases research​.

Don't miss this opportunity to join members of the King's Health Partners research and clinical community, and hear from experts involved in rare diseases research​.

This will be an online event and the session will be recorded for later viewing on the King's Health Partners learning hub.

-----

King's Health Partners Rare Disease Grand Round:  Hepatobiliary disease

The grand round will be chaired by Dr Cristina Dias, Group Leader and Clinical Reader in Genomics and Neurodevelopment, King’s College London, Consultant in Clinical Genetics and Genomics, Guy’s and St. Thomas’ NHS Foundation Trust, and Chair of the KHP Rare Disease Network.

Topics and speakers:

Mind over MASLD: Unravelling brain dysfunction in steatotic liver disease

Dr Anna Hadjihambi, Group Lead, UKRI Future Leaders Fellow, and Honorary Lecturer (Adj), The Roger Williams Institute of Liver Studies, King’s College London

Anna is a team lead at The Roger Williams Institute of Liver Studies in London, where she initiated the Liver-Brain axis group. She has recently been awarded a UKRI Future Leaders Fellowship to continue her investigations on the cerebral alterations arising due to steatotic liver disease, the possible mechanisms behind them, as well as the long-term effects of these conditions on the brain following resolution of liver disease.


Stromal cells in immune-mediated liver disease

Prof Philip Newsome, Professor of Hepatology, Director, The Roger Williams Institute of Liver Studies, and Director, King’s Health Partner’s Centre for Translational Medicine

-----

King’s Health Partners Academic Health Sciences Centre (AHSC) is a pioneering collaboration between King’s College London, and Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts.

Website: www.kingshealthpartners.org

Follow us on LinkedIn and X